Lili Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lili Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Huimin Li
Jiangxi Engineering Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases, Key Laboratory of Jiangxi Province for Biological Invasion and Biosecurity, Jiangxi Key Laboratory of Developmental Biology of Organs and Epigenetics, College of Life Sciences, Clinical Research Center of Jinggangshan University, Jinggangshan University, Ji'an 343009, China
1 shared publication - Jianhua Liu
School of Energy and Power Engineering, University of Shanghai for Science and Technology, Shanghai, China
1 shared publication - Jinfeng Liu
Department of Otorhinolaryngology Head and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
1 shared publication - Jingjing Yuan
Department of Otorhinolaryngology—Head and Neck Surgery, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
1 shared publication - Lili Kong
Binzhou Med Coll, Yantai Affiliated Hosp, Dept Endocrinol, 717 Jinbu St, Yantai 264100, Peoples R China
1 shared publication - Liwei Fu
Univ. Stuttgart (Germany)
1 shared publication
Latest Publications
- 3 November 2023
- Published by Springer Nature
- p. 195-225
HIV-Related Pulmonary Infection
- Open Access
- 27 July 2021
- Published by Impact Journals, LLC in Aging
- Vol. 13 (14) , 18423-18441
Yiqi Jiemin decoction alleviates allergic rhinitis in a guinea pig model by suppressing inflammation, restoring Th1/Th2 balance, and improving cellular metabolism
We investigated the mechanisms underlying the therapeutic effects of Yiqi Jiemin decoction (YJD), a traditional Chinese medicine (TCM), in the ovalbumin (OVA)-induced allergic rhinitis (AR) model in guinea pigs. YJD significantly decreased infiltration of mast cells and eosinophils into the nasal mucosa of AR model guinea pigs. YJD also increased expression of TGF-β in the nasal mucosa, restored the balance of Th1/Th2 immune cell responses, and decreased serum levels of various pro-inflammatory mediators, including histamine (HA), neuropeptide Y (NPY), acetylcholine (ACH), norepinephrine and immunoglobulin E (IgE). Metabolic analyses using liquid chromatography coupled with high-resolution mass spectrometry revealed that YJD improved cellular metabolism in AR model guinea pigs and increased serum levels of glycocholic acid while decreasing levels 1-palmitoyl lysophosphatidic acid. RNA-sequencing analysis identified BPIFB2 as a potential diagnostic biomarker and therapeutic target for AR. Functional enrichment analyses showed that YJD significantly inhibited cytokine secretion pathways in AR model guinea pigs. These findings demonstrate that YJD protects against OVA-induced AR in guinea pigs by suppressing inflammation in the nasal mucosa, restoring Th1/Th2 balance, and improving cellular metabolism.
- 27 July 2021
- Published by Impact Journals, LLC in Aging
- Vol. 13 (14) , 18423-18441
Open AccessYiqi Jiemin decoction alleviates allergic rhinitis in a guinea pig model by suppressing inflammation, restoring Th1/Th2 balance, and improving cellular metabolism
We investigated the mechanisms underlying the therapeutic effects of Yiqi Jiemin decoction (YJD), a traditional Chinese medicine (TCM), in the ovalbumin (OVA)-induced allergic rhinitis (AR) model in guinea pigs. YJD significantly decreased infiltration of mast cells and eosinophils into the nasal mucosa of AR model guinea pigs. YJD also increased expression of TGF-β in the nasal mucosa, restored the balance of Th1/Th2 immune cell responses, and decreased serum levels of various pro-inflammatory mediators, including histamine (HA), neuropeptide Y (NPY), acetylcholine (ACH), norepinephrine and immunoglobulin E (IgE). Metabolic analyses using liquid chromatography coupled with high-resolution mass spectrometry revealed that YJD improved cellular metabolism in AR model guinea pigs and increased serum levels of glycocholic acid while decreasing levels 1-palmitoyl lysophosphatidic acid. RNA-sequencing analysis identified BPIFB2 as a potential diagnostic biomarker and therapeutic target for AR. Functional enrichment analyses showed that YJD significantly inhibited cytokine secretion pathways in AR model guinea pigs. These findings demonstrate that YJD protects against OVA-induced AR in guinea pigs by suppressing inflammation in the nasal mucosa, restoring Th1/Th2 balance, and improving cellular metabolism.